GlassScriptPhysician profile
Lily Arendt
NPI 1801470380
$4,264.98
in general payments reported to CMS, 2019-2025
22 companies · $859 in 2025
The $859 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $712 · 2023: $1,302 · 2024: $1,392 · 2025: $859.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,511 · Entertainment: $42.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,510.85 |
| Entertainment | $42.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $618.14 | 2022-2024 | |
| Alcon Vision LLC | $489.59 | 2022-2025 | Wavelight Refractive Suite, Contoura Vision, Wavelight Ex500 Excimer Laser |
| Dompe US, INC. | $427.56 | 2022-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $412.55 | 2022-2024 | Cequa |
| Abbvie INC. | $376.32 | 2023-2025 | Durysta |
| Rxsight INC | $282.41 | 2023-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Johnson & Johnson Surgical Vision, INC. | $276.09 | 2022-2025 | Tecnis Iol, Tecnis Simplicity, One Series Ultra |
| Oyster Point Pharma, INC. | $219.57 | 2022-2024 | Tyrvaya, Ryzumvi |
| Sight Sciences, INC. | $207.66 | 2022-2024 | Tearcare System |
| Harrow Eye, LLC | $196.69 | 2024-2025 | Vevye, Triesence, Iheezo |
| Lkc Technologies, INC. | $132.24 | 2025 | |
| Amgen INC. | $124.99 | 2024 | Tepezza |
| Astellas Pharma US INC | $122.13 | 2023 | |
| Tarsus Pharmaceuticals, INC. | $91.43 | 2024-2025 | Xdemvy |
| Allergan, INC. | $80.88 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $64.09 | 2023-2024 | Xiidra, Miebo, Alrex |
| Optos, INC. | $42.25 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Thea Pharma INC. | $26.31 | 2024 | |
| Glaukos Corporation | $24.42 | 2022 | |
| Ocular Therapeutix, INC. | $20.98 | 2024 | Dextenza |
| Oasis Medical, INC. | $15.96 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.72 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lily Arendt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.